BORA PHARMACEUTICALS LTD (6472) - Cash Flow Conversion Efficiency
Based on the latest financial reports, BORA PHARMACEUTICALS LTD (6472) has a cash flow conversion efficiency ratio of 0.036x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$569.50 Million ≈ $17.94 Million USD) by net assets (NT$15.69 Billion ≈ $494.27 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
BORA PHARMACEUTICALS LTD - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how BORA PHARMACEUTICALS LTD's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read BORA PHARMACEUTICALS LTD (6472) financial obligations for a breakdown of total debt and financial obligations.
BORA PHARMACEUTICALS LTD Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BORA PHARMACEUTICALS LTD ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Better Life Commercial Chain Share Co Ltd
SHE:002251
|
0.006x |
|
Telecom Argentina
BA:TECO2
|
0.156x |
|
Shenzhen Desay Battery Technology Co Ltd
SHE:000049
|
0.015x |
|
Cellcom Israel Ltd
TA:CEL
|
0.111x |
|
STELLAR BANCORP DL -01
F:C9N0
|
0.008x |
|
4DMEDICAL Ltd
AU:4DX
|
0.446x |
|
Kidswant Children Products Co.Ltd.
SHE:301078
|
N/A |
|
Ninety One PLC
JSE:N91
|
-0.311x |
Annual Cash Flow Conversion Efficiency for BORA PHARMACEUTICALS LTD (2019–2024)
The table below shows the annual cash flow conversion efficiency of BORA PHARMACEUTICALS LTD from 2019 to 2024. For the full company profile with market capitalisation and key ratios, see 6472 market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-09-30 | NT$15.01 Billion ≈ $472.95 Million |
NT$980.81 Million ≈ $30.90 Million |
0.065x | -83.34% |
| 2023-09-30 | NT$11.77 Billion ≈ $370.69 Million |
NT$4.61 Billion ≈ $145.36 Million |
0.392x | +0.28% |
| 2022-09-30 | NT$5.14 Billion ≈ $161.95 Million |
NT$2.01 Billion ≈ $63.33 Million |
0.391x | -0.32% |
| 2021-09-30 | NT$3.15 Billion ≈ $99.32 Million |
NT$1.24 Billion ≈ $38.96 Million |
0.392x | +443.81% |
| 2020-09-30 | NT$2.46 Billion ≈ $77.65 Million |
NT$177.79 Million ≈ $5.60 Million |
0.072x | -48.53% |
| 2019-09-30 | NT$1.65 Billion ≈ $52.10 Million |
NT$231.77 Million ≈ $7.30 Million |
0.140x | -- |
About BORA PHARMACEUTICALS LTD
Bora Pharmaceuticals Co., LTD. engages in contract development, manufacture, and sale of pharmaceuticals in Europe, the United States, Taiwan, and internationally. The company operates through Sales, CDMO, and Other segments. It manufactures and sells generic, brand, and over the counter (OTC) drugs. The company also offers contract development and manufacturing services and technical services fo… Read more